Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 31, 1993

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Epstein-Barr Virus Infections
Interventions
BIOLOGICAL

EBV specific T cells

One injection of 2x10\^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00058812 - Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts | Biotech Hunter | Biotech Hunter